Baker Bros. Advisors LP Summit Therapeutics Inc. Transaction History
Baker Bros. Advisors LP
- $9.34 Billion
- Q3 2024
A detailed history of Baker Bros. Advisors LP transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Baker Bros. Advisors LP holds 24,424,865 shares of SMMT stock, worth $445 Million. This represents 5.73% of its overall portfolio holdings.
Number of Shares
24,424,865
Previous 23,222,222
5.18%
Holding current value
$445 Million
Previous $181 Million
195.31%
% of portfolio
5.73%
Previous 2.41%
Shares
5 transactions
Others Institutions Holding SMMT
# of Institutions
192Shares Held
75.8MCall Options Held
2.01MPut Options Held
2.84M-
Vanguard Group Inc Valley Forge, PA10.9MShares$199 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$144 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.44MShares$99.1 Million0.01% of portfolio
-
State Street Corp Boston, MA3.47MShares$63.2 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA3.1MShares$56.4 Million0.01% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $3.66B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...